{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:04:32Z","timestamp":1745640272204,"version":"3.40.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007112","name":"Universityof CapeTown","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001338","name":"University of Capetown","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.dmd.2025.100060","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:06:19Z","timestamp":1741467979000},"page":"100060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYP1A2 contributes to the metabolism of mefloquine: Exploration using in\u00a0vitro metabolism and physiologically-based pharmacokinetic modelling"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-3604","authenticated-orcid":false,"given":"Cleavon K.","family":"Cloete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preshendren","family":"Govender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-7755","authenticated-orcid":false,"given":"Nicholas","family":"Njuguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-7714","authenticated-orcid":false,"given":"Neil J.","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-646X","authenticated-orcid":false,"given":"Kelly","family":"Chibale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-2224","authenticated-orcid":false,"given":"Mathew","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100060_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/psp4.13013","article-title":"Development and application of a PBPK modeling strategy to support antimalarial drug development","volume":"12","author":"Abla","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/mol.64.3.659","article-title":"Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1","volume":"64","author":"Aklillu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib3","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1128\/AAC.00040-06","article-title":"Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria","volume":"50","author":"Ashley","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmd.2025.100060_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5455\/bcp.20110622071701","article-title":"CYP1A2\u22171F polymorphism decreases clinical response to clozapine in patients with schizophrenia","volume":"21","author":"Balibey","year":"2011","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bulletin of Clinical Psychopharmacology"},{"key":"10.1016\/j.dmd.2025.100060_bib5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/0006-2952(92)90638-Y","article-title":"Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs","volume":"43","author":"Bangchang","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/clpt.1990.168","article-title":"Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers","volume":"48","author":"Boudreau","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100060_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s002280050100","article-title":"Stereoselective pharmacokinetics of mefloquine in young children","volume":"50","author":"Bourahla","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-200304000-00003","article-title":"Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine","volume":"23","author":"Carrillo","year":"2003","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-3075-5","article-title":"An in\u00a0vitro toolbox to accelerate anti-malarial drug discovery and development","volume":"19","author":"Charman","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.dmd.2025.100060_bib10","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0024-3205(00)00546-4","article-title":"Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes","volume":"66","author":"Fontaine","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.dmd.2025.100060_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1989.tb05413.x","article-title":"Divided-dose kinetics of mefloquine in man","volume":"28","author":"Franssen","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jps.2600830613","article-title":"Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses","volume":"83","author":"Gimenez","year":"1994","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100060_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2125.1997.00633.x","article-title":"Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose","volume":"44","author":"Hellgren","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib14","series-title":"Presented at: 11th International Conference on AIDS","article-title":"Assessment of multiple doses of ritonavir on pharmacokinetics of theophylline","author":"Hsu","year":"1996"},{"key":"10.1016\/j.dmd.2025.100060_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230975","article-title":"In\u00a0vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum (Trichosurus vulpecula)","volume":"15","author":"Izes","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.dmd.2025.100060_bib16","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00213-014-3446-0","article-title":"Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in\u00a0vitro","volume":"231","author":"Janowsky","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.dmd.2025.100060_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.100375","article-title":"Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption","volume":"37","author":"Jogiraju","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100060_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bcp.13764","article-title":"Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children","volume":"85","author":"Johnson","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","article-title":"Clinical pharmacokinetics of mefloquine","volume":"19","author":"Karbwang","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100060_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2125.2001.01393.x","article-title":"Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers","volume":"51","author":"Khaliq","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100060_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2125.1987.tb03133.x","article-title":"Studies of mefloquine bioavailability and kinetics using a stable isotope technique: A comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers","volume":"24","author":"Looareesuwan","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00193485","article-title":"Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers","volume":"47","author":"Martin","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000238195","article-title":"Multiple-dose kinetic study of mefloquine in healthy male volunteers","volume":"29","author":"Mimica","year":"1983","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmd.2025.100060_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/omi.2021.0199","article-title":"Warfarin pharmacogenomics for precision medicine in real-life clinical practice in southern Africa: Harnessing 73 variants in 29 pharmacogenes","volume":"26","author":"Muyambo","year":"2022","journal-title":"OMICS"},{"key":"10.1016\/j.dmd.2025.100060_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/dmpt-2016-0028","article-title":"Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction","volume":"31","author":"Njuguna","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.dmd.2025.100060_bib27","first-page":"301","article-title":"Management of obsessive-compulsive disorder with fluvoxamine extended release","volume":"5","author":"Ordacgi","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.dmd.2025.100060_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cpt197824140","article-title":"Effect of smoking on caffeine clearance","volume":"24","author":"Parsons","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100060_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00228-011-1189-y","article-title":"Prediction of drug clearance in a smoking population: Modelling the impact of variable cigarette consumption on the induction of CYP1A2","volume":"68","author":"Plowchalk","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12936-015-0916-8","article-title":"Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults","volume":"14","author":"Rattanapunya","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.dmd.2025.100060_bib31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dku430","article-title":"Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria","volume":"70","author":"Reuter","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.dmd.2025.100060_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1211\/0022357001777243","article-title":"Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers","volume":"52","author":"Ridtitid","year":"2000","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2710.2005.00651.x","article-title":"Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers","volume":"30","author":"Ridtitid","year":"2005","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.dmd.2025.100060_bib34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/v14020374","article-title":"Unlike chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells","volume":"14","author":"Sacramento","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.dmd.2025.100060_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000238513","article-title":"Urinary excretion of mefloquine and some of its metabolites in African volunteers at steady state","volume":"33","author":"Schwartz","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmd.2025.100060_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000238062","article-title":"Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites","volume":"28","author":"Schwartz","year":"1982","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmd.2025.100060_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152677","article-title":"The interactions of P-glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation","volume":"11","author":"Senarathna","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.dmd.2025.100060_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0009-9236(99)70010-X","article-title":"Population pharmacokinetics of mefloquine in patients with acute falciparum malaria","volume":"66","author":"Simpson","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100060_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jps.22249","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Mefloquine hydrochloride","volume":"100","author":"Strauch","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100060_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2003.11.003","article-title":"Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells","volume":"484","author":"Traebert","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100060_bib41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2125.1993.tb00424.x","article-title":"Cigarette smoking enhances the elimination of quinine","volume":"36","author":"Wanwimolruk","year":"1993","journal-title":"Br J Clin Pharmacol"},{"year":"2022","series-title":"WHO Guidelines for malaria","key":"10.1016\/j.dmd.2025.100060_bib42"},{"key":"10.1016\/j.dmd.2025.100060_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:34:45Z","timestamp":1745577285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625090695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0090955625090695"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100060","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP1A2 contributes to the metabolism of mefloquine: Exploration using in\u00a0vitro metabolism and physiologically-based pharmacokinetic modelling","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100060"}}